Cedars-Sinai receives $11.99 million from CIRM to launch ALS clinical trial

2021-09-07T16:20:37+00:00

Cedars-Sinai receives $11.99 million from CIRM to launch ALS clinical trial Cedars-Sinai has been awarded $11.99 million by California's stem cell agency to launch a clinical trial testing a potential gene and stem cell therapy for amyotrophic lateral sclerosis (ALS). ALS, or Lou Gehrig's disease, is a progressive neurodegenerative disease that damages nerve cells known as motor neurons in the brain and spinal cord that control voluntary muscle movement. It affects an estimated 16,000 people in the U.S. and is usually fatal within five years of diagnosis. There is no known cure and only limited treatments that may slow progression [...]

Cedars-Sinai receives $11.99 million from CIRM to launch ALS clinical trial2021-09-07T16:20:37+00:00

Healey Center for ALS in partnership with ALS Finding a Cure announces the 2021 ALS Scholars in Therapeutics Recipients

2021-12-15T14:50:48+00:00

Class of 2021 The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) in partnership with ALS Finding a Cure (ALSFAC) selected four recipients for their inaugural global two-year ALS Scholars in Therapeutics program. The program received an outstanding pool of global applications from 6 countries. This year’s selected recipients are Juliet Goldsmith, PhD of University of Pennsylvania, Matthew Anthony White, PhD of Kings College London, Brian Jude Joseph, PhD of Harvard University and Su Min Lim, PhD of Massachusetts General Hospital, Harvard Medical School. Learn about the ALS Scholars Program. [...]

Healey Center for ALS in partnership with ALS Finding a Cure announces the 2021 ALS Scholars in Therapeutics Recipients2021-12-15T14:50:48+00:00

ALSFAC-Funded Project Announces Successful ALS Clinical Trial and High-Profile Publication

2021-09-07T16:20:37+00:00

ALSFAC-Funded Project Announces Successful ALS Clinical Trial and High-Profile Publication Amylyx, a start-up biotech company developing new treatments for ALS supported by ALS Finding a Cure®, and Mass General Hospital, announced the publication of results from its successful pivotal stage ALS clinical trial in the prestigious New England Journal of Medicine (NEJM). ALS Finding A Cure® provided two grants to Amylyx: the first in collaboration with Cure Alzheimer’s Disease to support required preclinical toxicology studies, and the second to fund this trial in collaboration with The ALS Association as part of the ALS ACT initiative.  The clinical trial, known as [...]

ALSFAC-Funded Project Announces Successful ALS Clinical Trial and High-Profile Publication2021-09-07T16:20:37+00:00

ALSFAC Funded Research Turns Off Key Gene in Families with ALS

2021-09-07T16:20:37+00:00

ALSFAC Funded Research Turns Off Key Gene in Families with ALS Researchers at the University of Massachusetts Medical School and Massachusetts General Hospital report progress on a potential new weapon against the fatal nerve disease ALS. Read More Report Progress

ALSFAC Funded Research Turns Off Key Gene in Families with ALS2021-09-07T16:20:37+00:00

Team of Five Labs Launches Novel Attack on ALS

2021-09-07T16:20:37+00:00

Team of Five Labs Launches Novel Attack on ALS Amyotrophic Lateral Sclerosis (ALS) can arise from aberrant genes. A group of five Brown University professors proposes that a cure may also come from aberrant genes – genetic mutations that suppress ALS. A new research grant supports their comprehensive investigation of ALS in flies, worms, mice and human cells.

Team of Five Labs Launches Novel Attack on ALS2021-09-07T16:20:37+00:00

Progress Coming in Amyotrophic Lateral Sclerosis, but Rigorous Studies Needed

2021-09-07T16:20:37+00:00

Progress Coming in Amyotrophic Lateral Sclerosis, but Rigorous Studies Needed The community of individuals living with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, has endured many false hopes for promising therapies and is still waiting for the first disease-modifying drug. Nevertheless, "we have made huge progress in the last decade in ALS," Merit Cudkowicz, professor of neurology at Harvard Medical School and chief of the neurology service and director of the MDA ALS clinic at Massachusetts General Hospital, told participants in an integrated neuroscience session on ALS at the American Academy of Neurology... READ MORE [...]

Progress Coming in Amyotrophic Lateral Sclerosis, but Rigorous Studies Needed2021-09-07T16:20:37+00:00

Johns Hopkins University, Cedars-Sinai and Massachusetts General Hospital Announce Groundbreaking ALS Research Project of Answer ALS

2021-09-07T16:20:37+00:00

Johns Hopkins University, Cedars-Sinai and Massachusetts General Hospital Announce Groundbreaking ALS Research Project of Answer ALS Research Designed to Fully Understand and Defeat ALS; “Big Data” Technology Will Drive Unprecedented Analysis Capability $20 Million in Funding from Committed Team of Donors, including the National Football League, the PGA TOUR, ALS Finding a Cure (a project of the Leandro P. Rizzuto Foundation), Travelers, The Fishman Family and The Bari Lipp Foundation BALTIMORE, LOS ANGELES and BOSTON, September 9, 2015 – Johns Hopkins University’s Robert Packard Center for ALS Research, Cedars-Sinai Medical Center’s Regenerative Medicine Institute and the Massachusetts General Hospital Neurological [...]

Johns Hopkins University, Cedars-Sinai and Massachusetts General Hospital Announce Groundbreaking ALS Research Project of Answer ALS2021-09-07T16:20:37+00:00

Karyopharm Advancing Neuroprotective SINE™ Compounds in Amyotrophic Lateral Sclerosis (ALS)

2021-09-07T16:20:38+00:00

Karyopharm Advancing Neuroprotective SINE™ Compounds in Amyotrophic Lateral Sclerosis (ALS) Preclinical efficacy of SINE™ compounds validated in journal Nature publication–  Presentations of ALS abstracts at upcoming AAN and SfN meetings – Collaborator grant funding supports Karyopharm’s ALS research– Newton, Mass. – September 3, 2015 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported that its SINE™ nuclear transport compounds are being evaluated for the treatment of Amyotrophic Lateral Sclerosis (ALS) and that preclinical data abstracts will be presented at two upcoming neuroscience meetings. A recent publication appearing in the journal Nature confirmed that nuclear transport is disrupted in [...]

Karyopharm Advancing Neuroprotective SINE™ Compounds in Amyotrophic Lateral Sclerosis (ALS)2021-09-07T16:20:38+00:00

Coya Raises $10M to Advance T-cell Therapy Now in Phase 2 ALS Trial

2021-09-07T16:20:38+00:00

Coya Raises $10M to Advance T-cell Therapy Now in Phase 2 ALS Trial Coya Therapeutics has raised $10 million in funding to advance the development of ALS001, a potential regulatory T-cell (Treg) therapy aiming to halt amyotrophic lateral sclerosis (ALS) progression, now in a Phase 2 study in patients. Proceeds raised in this series A funding round will also be used to introduce into testing similar treatments for other neurodegenerative disorders. “Patients with neurodegenerative diseases are in desperate need of transformative therapeutic options; harnessing the neuro-protective effects of Treg cell therapy shows great potential in unlocking a new treatment paradigm [...]

Coya Raises $10M to Advance T-cell Therapy Now in Phase 2 ALS Trial2021-09-07T16:20:38+00:00

Answer ALS Launches ‘The Data is Here’ Campaign to Announce the Release of the World’s Largest Open Sourced ALS Data Portal

2021-09-07T16:20:38+00:00

Answer ALS Launches 'The Data is Here' Campaign to Announce the Release of the World's Largest Open Sourced ALS Data Portal The Answer ALS Data Portal seeks to empower researchers around the globe with the data needed to finally answer ALS NEW ORLEANS, Jan. 8, 2021 /PRNewswire/ -- Answer ALS, in cooperation with the Stephen Hawking Foundation, launches "The Data is Here" campaign on January 8 and on what would have been the famed Theoretical Physicist's 79th birthday. The campaign features a video tribute to Stephen Hawking and his tireless efforts to solve complex universal questions, while living with ALS for over 50 years. [...]

Answer ALS Launches ‘The Data is Here’ Campaign to Announce the Release of the World’s Largest Open Sourced ALS Data Portal2021-09-07T16:20:38+00:00
Go to Top